[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Navamindradhiraj University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100592166","comparing-super-high-flux-and-high-flux-dialyzer-performance-among-hemodialysis-patient-with-sepsis--a-randomized-control-trial-100592166",false,"NCT06989892","Comparing Super High-flux and High-flux Dialyzer Performance Among Hemodialysis Patient With Sepsis : a Randomized Control Trial","Inclusion Criteria:\n\n* ESKD patients who have sepsis condition with high interleukin-6 (IL-6 \\> 50 pg\u002Fml)\n\nExclusion Criteria:\n\n* Patients who needed dialysis with continuous kidney replacement therapy, vulnerable patient, include pregnant woman, patient who expected to pass away within the 24 hours.\n* Patients who have the history of allergic dialyzer reaction to dialyzer which used in this trial.","ALL","18 Years",{"count":18,"type":19},202,"ESTIMATED","INTERVENTIONAL",[22],"NA","Comparing the efficacy of superhigh-flux dialyzer with high-flux dialyzer in ESKD patient who have sepsis to improve mortality and sepsis outcome, an open label randomized control trial.",[25,26,27],"The Efficacy and Safety for Super High-flux Dialyzer in Case of Sepsis in ESKD","End Stage Kidney Disease (ESRD)","Sepsis",[29,30,31,32],"Superhighflux","hemodialysis","end stage kidney disease","sepsis","RECRUITING","2025-05-19",{"date":36,"type":37},"2025-05-25","ACTUAL",{"date":39,"type":37},"2024-07-25",{"date":41,"type":19},"2026-10-01",{"name":43,"class":44},"Navamindradhiraj University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100528768","phase-3-effects-of-antiplatelet-and-antioxidant-agents-on-drusen-progression-a-pilot-prospective-cohort-study-100528768","NCT06165068","Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study","Inclusion Criteria:\n\n* Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron.\n* Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity.\n* Age range: 50-85 years\n* Patients who have previously used antiplatelet drugs.\n\nExclusion Criteria:\n\n* Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization)\n* Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema.\n* Patient with a history of intravitreal anti-VEGF injection or macular laser.\n* Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications.","50 Years","85 Years",{"count":55,"type":19},174,[57],"PHASE3","The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg\u002Fday or clopidogrel 75 mg\u002Fday) with or without a combination of antioxidants (N-acetylcysteine 600 mg\u002Fday) in a dry AMD patient with large drusen.\n\nParticipants will divided in to three groups.\n\n* Participants who were already taking low dose antiplatelet medications.\n* Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator\n* Participants does not use any medications.",[60],"Dry Age-related Macular Degeneration","2023-12-11",{"date":63,"type":37},"2023-12-15",{"date":65,"type":19},"2023-12",{"date":67,"type":19},"2026-09",{"name":43,"class":44},""]